Mylan announces patent challenge for generic Nexavar

PITTSBURGH — Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug appliation for sorafenib tablets, the generic version of Nexavar. 

 

Mylan believes that it is the first company to have filed a "substantially complete" ANDA for the product. The suit was filed against the company in the United States District Court of Delaware.

 

Nexavar had sales in the United States of $48 million for the 12 months ending Dec. 31, according to IMS Health data. The drug is used to treat certain types of cancers.